

Job Advert (Iceland)

- Formulation Project Manager -

Location: Reykjavik, Iceland

Position summary:

In the context of the company growth, Oculus is currently looking for a Formulation Project Manager for its Research Laboratory located in Reykjavik, Iceland. This laboratory is responsible for drug-product formulation, and the Formulation Project Manager oversees the whole predevelopment process from early-stage project design up to the final lead formulation readiness for industrial scale-up.

Main Responsibilities:

- Ophthalmic formulation design.
- Design and perform experiments for drug pre-formulation, formulation, and process definition.
- Analytical method development.
- Product manufacturing process definition.

Required skills and competencies:

- Bachelor's and/or post-graduate degree or equivalent in chemistry or pharmaceutical sciences, with at least 5 years of experience in either pharmaceutical or biotechnology industry.
- Experience of formulation and manufacturing process development, ideally of sterile products.
- Strong hands-on expertise in analytical method development, incl. HPLC.
- An experience in drug registration dossier submission process in either USA or EU (CTD/Module 3) would be considered as a plus.
- Thorough understanding of cGMP, pharmacopeia testing and regulatory requirements for drug development and approval.
- Good knowledge of written and spoken English.
- Good communication and teamwork skills.

Please send your CV with motivation letter to umsokn@oculis.com before 15th June, 2021.

About Oculus:

Headquartered in Lausanne, Switzerland with global operations in Europe and the U.S., Oculus is a biopharmaceutical company focused on developing transformative innovative ophthalmic treatments to improve the sight and lives of patients. Oculus has a robust and expansive development portfolio including late-stage novel topical (eye drop) treatments, which are non-invasive and represent an unprecedented technical advance in ocular drug delivery, potentially for the back-of-the-eye diseases that are currently managed by invasive methods only, such as intraocular injections or implants. In addition, Oculus' formulation discovery focus and capabilities enable the development of a pipeline of topical drugs targeting sight-threatening eye diseases that affect both the anterior and posterior segments of the eye. To learn more, please visit www.oculis.com